- 12 oral surgery updates in 2026
- 5 ASC, MOB deals in California
- Hidden OR capacity challenges: 8 perioperative leaders on what’s draining surgical time
- The Aspen Group’s 3-year growth recap: 40 moves
- Florida State University set to acquire Tallahassee hospital
- How Confusing Financial Journeys Undermine Revenue and Trust
- How Confusing Financial Journeys Undermine Revenue and Trust
- Misalignment, Not Malice: Rethinking Generational Conflict in Healthcare
- If AI ‘adds friction, it fails’: How Mayo Clinic scales technology
- As maternity units close, AdventHealth restores OB care in rural Kansas
- Oklahoma officials warn of new opioid
- The new metrics of healthcare technology ROI: What matters to healthcare leaders
- Hoag to launch transplant center in 2027
- MercyOne hospital to transition labor and delivery services
- MercyOne hospital to transition labor and delivery services
- Southeast metros lead US population growth as national gains slow
- 8 Medicare Advantage numbers to know in 2026
- 17 Senate Dems push back on 2027 ACA proposal
- Providence hospital closes inpatient pediatric unit
- Michigan finalizes Medicaid mental health assessment policy changes
- 10 financial notes on USPI’s growth over the past 3 years
- 15 new orthopedic practice, center openings in Q1
- The oral surgery technological revolution
- From Anxiety to Action: How Ambulatory Leaders Are Rebuilding Margins in 2026
- Where GI training may fall short
- What it took to become the world’s first ASC to offer Stryker’s robotic knee tech
- Medtronic’s win in spinal cord stimulator lawsuit upheld
- How the Trump Administration Uses Migrant Kids To Find and Detain Family Members
- Heartland Dental’s 3-year growth recap: 30+ moves
- Cencora’s $10B+ physician acquisition spree: A breakdown
- Tennessee physician practice acquired
- The FTC is coming for healthcare consolidation: 10 things physicians need to know
- Adventist Health sees momentum from insourcing revenue cycle operations
- Oral GLP-1s, COVID preventatives: 3 more drugs in the pipeline, Optum says payers should watch
- Unlicensed dentistry cases, DSO deals, legislation & more: 10 dentistry updates in Virginia
- Missouri system debuts mobile behavioral health unit
- Yale researchers study GLP-1’s potential for SUD
- Texas dental school receives $6.5M to expand pediatric dental, medical programs
- North Carolina autism provider to expand therapy access
- $3M Verdict Links Social Media to Anxiety and Depression
- West Virginia hospital to end OB delivery services
- 6 DSOs making headlines
- California hospital’s finances improve, cash position remains ‘dire’
- 1 in 5 metro markets face inpatient monopoly: 7 notes
- Minnesota system faces uncertainty amid Medicare delays
- Ohio county approves behavioral health crisis center plan
- The White House Delays CDC Pick
- New COVID 'Cicada' Variant Is Spreading — What Experts Want You To Know
- Op-ed: Empathy meets efficiency—how the responsible use of AI can transform Medicare
- Family Caregivers Provide $1 Trillion In Annual Labor, AARP Says
- ‘Health Doesn’t Need to Be Ludacris’: Bayer signs rapper-actor to multivitamin campaign
- Rocket plots measured trajectory for new gene therapy Kresladi after clearance to launch from FDA
- Healthy Lab Results May Mask Future Risks for Kids with Obesity
- At-Home Chemotherapy Is Safe, Feasible, Pilot Study Indicates
- What You Do While Sitting Could Predict Dementia Risk
- New Cholesterol Guidelines: What Patients and Caregivers Need to Know
- Want A Bootlicking Yes Man? Ask An AI Chatbot For Advice, Study Warns
- Specially Coated Implants Better For Breast Cancer Patients, Study Finds
- Trump Team Claims Successes Against ACA Fraud While Pushing for More Controls
- Give and Take: Federal Rural Health Funding Could Trigger Service Cuts
- Fierce Pharma Asia—Takeda’s $1.3B reorg; India’s GLP-1 floodgates; Gilead’s $2.2B buy of a China NewCo
- Where are you with EUDAMED?
- Where are you with EUDAMED?
- HL7 Launches Real‑Time Medical Device Interoperability Accelerator
- HL7 Launches Real‑Time Medical Device Interoperability Accelerator
- Two GA Tech ATDC Startups — Nephrodite and OrthoPreserve — Secure FDA Breakthrough Device Designation
- Two GA Tech ATDC Startups — Nephrodite and OrthoPreserve — Secure FDA Breakthrough Device Designation
- Artificial Intelligence: ROI, not Clinical Autonomy, Leads Operational Workflows
- Artificial Intelligence: ROI, not Clinical Autonomy, Leads Operational Workflows
- Medtronic and Merit Medical Systems distribution agreement for new, ViaVerte basivertebral nerve ablation system
- Medtronic and Merit Medical Systems distribution agreement for new, ViaVerte basivertebral nerve ablation system
- Breakthrough Device Designation for Noah Labs Vox Heart Failure Detection Device
- Breakthrough Device Designation for Noah Labs Vox Heart Failure Detection Device
- Why private practice dentistry needs a better model
- CareQuest Innovation Partners, Kno2 collab on medical-dental data integration
- Nonprofit highlights rural opioid care strategies
- Vitana Pediatric & Orthodontic Partners adds Florida practice
- What the Health? From KFF Health News: A Headless CDC
- 20 behavioral health leaders challenge industry assumptions
- Recordati confirms it's weighing CVC Capital buyout offer of $12.6B
- 3 California behavioral health centers to close amid funding shifts
- Indiana bars autism therapy provider from Medicaid billing: Wall Street Journal
- UnitedHealth shareholder sues over proposal to include details on integration in annual proxy
- SCAN taps biopharma, CMS vet Aman Bhandari as its first chief AI officer
- Infosys to acquire Optimum Healthcare IT in $465M deal
- DOJ alleges NewYork-Presbyterian forces payers into anticompetitive 'all-or-nothing' contracts
- FDA Warns Biotech Firm Over Cancer Drug Anktiva Claims
- Bees and Hummingbirds May Be Consuming Small Amounts of Alcohol
- Two States Sue Cord Blood Company Over Misleading Claims
- New WHO Guidance Aims To Speed Tuberculosis Testing
- As questions swirl around ATTR competition, Alnylam plots path to market leadership for Amvuttra
- Trump admin delays nomination for new CDC director past deadline
- Outspoken ACIP member steps down amid vaccine panel uncertainty: reports
- Egg-based drugmaker Neion Bio emerges from stealth to cook up multi-product biosimilar collab
- Genentech walks the walk in lupus as sponsor of annual awareness and fundraising event
- Study Reveals How Many Americans Consider Using a Gun
- Massive Study Finds Stress and Grief Don’t Cause Cancer
- Ultra-Processed Foods Harm Fertility In Both Men And Women, Studies Reveal
- Small Daily Habits Can Add Up To Better Heart Health
- Ritalin Might Protect ADHD Kids' Long-Term Mental Health, Study Finds
- Can You Drink Enough Fluids To Prevent Kidney Stones? Maybe Not, New Study Says
- Clasp, loan-linked hiring tool for employers, clinches $20M to expand amid federal loan caps
- Taking a GLP-1? Doctors Say Not To Forget About Movement and Mental Health
- OpenEvidence rolls out AI medical coding feature
- CDC’s Acting Chief Promises a Return to Stability in a Tumultuous Moment
- Remarks at the Financial Stability Oversight Council Meeting
- RWJF: Between 5M and 10M people could lose Medicaid coverage in 2028 under work requirements
- New therapy animal program aims to support 100K patients, providers
- Pulse check on Lilly's GLP-1 fortunes
- Gen Z nurses prioritize schedule flexibility, need more manager interactions to avoid turnover
- How pharma marketers can capitalize on HCPs’ AI, social media and streaming habits
- Federal Officials Investigate States That Require Abortion Coverage
- Corcept's lead drug bounces back from FDA snub with different approval as Lifyorli in ovarian cancer
- Ionis slashes Tryngolza's price tag by 93% ahead of anticipated label expansion
- FDA approves Denali's Hunter syndrome drug, handing rare disease community a win
- Baby Walkers Sold on Amazon Recalled Over Fall Risk
- Want To Protect Your Brain? Science Says Exercise
- HelloFresh Pizza Recall Issued in 10 States Over Metal Risk
- Clinical Trials Have Too Much Data…That’s the Problem.
- Clinical Trials Have Too Much Data…That’s the Problem.
- CMS reveals new Medicaid model that supports coordination for children with complex needs
- Novartis sued by breast cancer patient over branded drug websites’ data-sharing practices
- Takeda targets $1.3B in cost savings in further restructuring
- Biogen pays $20M upfront to tap into Alteogen's subQ delivery tech
- 'Universal Donor' Blood Supplies Dangerously Low, Study Warns
- Why Stepping Outside May Help You Eat Better
- U.S. Medicine, Science Facing An Online Misinformation Siege, Poll Concludes
- Childhood Obesity Undercuts The American Dream For Some, Study Says
- Inclusive High Schools Benefit All Students, Not Just LGBTQ Teens
- Parental Loss Due to Drugs, Violence Raises Child Death Risk by 2,000%
- As Boehringer touts US launches, board chairman worries EU is 'falling further behind'
- The evolving state of exome and genome sequencing
- Demoralized CDC Workforce Reels From Year of Firings, Funding Cuts, and a Shooting
- An Arm and a Leg: Steep Health Care Costs Steer Americans to Tough Decisions
- Qualified Health locks in $125M in fresh funding to scale enterprise AI at health systems
- Misery Loves [Investment] Company?: Remarks at the 2026 Investment Company Institute Investment Management Conference
- Study: Nearly 1 in 5 pediatric hospital deaths involve sepsis
- As expansions come online, CDMO Hovione aims to meet industry's 'dual supply and sourcing' zeal: exec
- Opening Remarks at the Digital Asset Summit 2026
- CVS Caremark, FTC reach settlement in insulin pricing case
- UCB unveils plan to build $2B biologics plant near its US headquarters in Atlanta
- PeaceHealth sued over plans to tap out-of-state staffer ApolloMD for Oregon EDs
- New Lyme Disease Vaccine Shows Strong Results in Trial
- TrumpRx Adds Diabetes, COPD Drugs at Steep Discounts
- Highmark reports $175M net loss for 2025 as financial headwinds batter health plan
- Listen to the Latest ‘KFF Health News Minute’
- Abivax hires commercial chief from Takeda to infuse Entyvio expertise into IBD launch prep
- ImmunityBio hit with FDA warning letter over Anktiva promotions in TV ad, podcast episode
- Alcohol Prep Pads Recalled Over Bacteria Risk, Cardinal Health Says
- Fewer patients traveled for abortions in 2025 as telehealth care increased, report finds
Think the author of this post has the entities suing the Federal government wrong. It is the Dayton Chamber of Commerce suing, with the backing of the U.S. Chamber of Commerce:
US Chamber of Commerce sues over government's drug pricing power
By Jonathan Stempel - June 9, 2023June 9 (Reuters) - The U.S. Chamber of Commerce on Friday sued the federal government, challenging a new law that for the first time gives Medicare the power to negotiate drug prices with pharmaceutical companies.
In a complaint filed in federal court in Dayton, Ohio, the chamber said the pricing program violated drugmakers' due process rights under the U.S. Constitution by giving the government "unfettered discretion" to dictate maximum prices.
It also said the program would impose exorbitant penalties on drugmakers that don't accept those prices, and amounted to an ultimatum: "agree to whatever price the government names, or we'll smash up your business."
The U.S. Department of Health and Human Services administers Medicare through its Centers for Medicare & Medicaid Services.
A spokeswoman said the agency will vigorously defend the program, which is already helping lower healthcare costs for older adults and people with disabilities. "The law is on our side," she added.
Friday's lawsuit by the chamber, one of the most powerful U.S. business groups, came three days after Merck & Co (MRK.N) filed a similar lawsuit in Washington, D.C.
Both lawsuits contended that price controls would force drugmakers to pull back on developing new drugs, causing long-term harm to Americans and their health.
Other drugmakers have also objected to the pricing program, which is part of last year's Inflation Reduction Act. Pricing changes following negotiations on 10 costly drugs selected by CMS would take effect in 2026.
Americans pay more for prescription drugs than prices in any other country.
The Biden administration hopes to save $25 billion annually by 2031 by having Medicare, the government health plan for people 65 and over, negotiate prices.
White House spokeswoman Karine Jean-Pierre said on Tuesday the government was confident it would win the Merck case.
"There is nothing in the Constitution that prevents Medicare from negotiating lower drug prices," she said.
The chamber also warned that allowing the pricing program would set a bad precedent.
"After all, if the government can impose price controls in the pharmaceutical industry, why not elsewhere?" Chief Policy Officer Neil Bradley said in a statement.
The case is Dayton Area Chamber of Commerce et al v Becerra et al, U.S. District Court, Southern District of Ohio, No. 23-00156.
Now up to 4 Pharma/Chamber of Commerse lawsuits contesting Medicare drug price negotiation.
Pharmaceutical trade group sues US over Medicare drug price negotiation plans
NEW YORK, June 21 (Reuters) - The Pharmaceutical Research and Manufacturers of America (PhRMA), the leading industry lobby group, and two other organizations on Wednesday said they were suing the U.S. government to block enforcement of a program that gives Medicare the power to negotiate drug prices.
In a complaint filed in a federal court in Texas, PhRMA along with the National Infusion Center Association and the Global Colon Cancer Association, which counts PhRMA and some drug companies as members, said the drug price negotiation program was unconstitutional.
This marks the fourth lawsuit challenging the law, which is part of President Joe Biden’s signature Inflation Reduction Act (IRA), after separate legal challenges by Merck & Co (MRK.N), Bristol Myers Squibb (BMY.N), and the influential business group the U.S. Chamber of Commerce.
The pharmaceutical industry claims negotiating prices of its products with the government health plan for Americans age 65 and older will curtail profits and compel them to pull back on developing groundbreaking new treatments.
PhRMA represents many of the largest pharmaceutical companies in the world, including Merck and Bristol Myers.
Americans pay more for prescription medicines than any other country. The Biden administration's drug pricing reform aims to save $25 billion annually by 2031 through price negotiations for the drugs most costly to Medicare.
The latest lawsuit argues that the "unrestrained authority" given to the Department for Health and Human Services (HHS) by Congress conflicts with the United States' separation-of-power principle.
"Congress took a series of unconstitutional shortcuts, giving the executive branch the open ended task of replacing market based prices in Medicare with an entirely new set of prices at the (Medicare) agency's own choosing," PhRMA general counsel James Stansel said at a press conference.
The lawsuit also contends that the price negotiation program violates the U.S. Constitution's Eight Amendment, which protects against excessive fines, and Fifth Amendment by exempting key decisions from public input.
PhRMA and the other two groups are seeking an injunction against the price caps and a declaration that the IRA's price negotiation is unconstitutional.
The negotiations are scheduled to start in September after the agency that runs Medicare and Medicaid releases its list of 10 costly drugs initially selected for the process, with the agreed prices taking effect in 2026.
The suits challenging the plan have been filed in four different federal courts, with Merck's in Washington, D.C., the Chamber of Commerce in Ohio and Bristol Myers' in New Jersey.
In response to the previous lawsuits, the White House said there is nothing in the U.S. Constitution that prevents Medicare from negotiating lower drug prices.
A spokesperson for HHS on Wednesday said the law is on its side.
“As the (HHS) secretary has already made clear, we will vigorously defend the president’s drug price negotiation law, which is already helping to lower healthcare costs for seniors and people with disabilities."
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.

















